TIDMMED

RNS Number : 0725Z

Intelligent Ultrasound Group PLC

08 January 2020

Intelligent Ultrasound Group plc

("Intelligent Ultrasound" or the "Company" or the "Group")

Trading Update

Intelligent Ultrasound Group plc (AIM: MED), the ultrasound artificial intelligence (AI) software and simulation company, announces that Group revenue for the year to 31 December 2019, which is currently generated entirely by the Group's Simulation Division, is expected to grow by around 10% from the GBP5.3m achieved in 2018 to between GBP5.7m and GBP5.9m. The Group is pleased that the Division continued to show year on year growth and the important agreement signed with FUJIFILM SonoSite Inc. in the second half of the year, will help increase future sales in the Division's point-of-care ultrasound (POCUS) training market.

The Group's pre-revenue Clinical Artificial Intelligence Division had a very successful year, meeting all its commercial and development milestones. By signing its first long-term licence and co-development agreement in July 2019 with one of the world's leading ultrasound equipment manufacturers for its AI-based real-time ultrasound imaging software, the Group made a significant advance in validating its commercial model. Following the completion of the pre-regulatory development of AnatomyGuide, the Division's latest AI-based real-time software product, commercial discussions are now being progressed to bring AnatomyGuide to market. To support future developments, the Division's AI image database has been expanded so it now exceeds over four million ultrasound images.

The EBITDA loss for the year is expected to be between GBP3.3m and GBP3.4m (2018: loss, GBP2.7m). This includes approximately GBP2.0m (2018: GBP1.3m) of primarily R&D costs attributable to investment in the Group's Clinical Artificial Intelligence Division. Group management, PLC costs and share-based payment charges included in the loss are expected to be GBP1.0m (2018: GBP0.9m).

GBP5.9m net of costs was received in August 2019 from the successful placing and open offer. Cash in bank at 31 December 2019 was GBP7.3m (2018: GBP5.6m).

Stuart Gall, Group CEO, commented: "This has been a strong year for the Group. The Clinical Artificial Intelligence Division has performed particularly well, signing its first licensing agreement with a major OEM and progressing commercial discussions for its second AI software product. The reception the Company received at the annual Radiological Society of North America meeting (RSNA) in Chicago was also particularly encouraging. The Simulation Division has worked hard to continue growing revenue and we are confident of continuing the Group's revenue growth in 2020."

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 
  Intelligent Ultrasound Group plc                                                       www.intelligentultrasound.com 
  Stuart Gall, CEO                                                                            Tel: +44 (0)29 2075 6534 
   Helen Jones, Group Finance Director 
 
  Cenkos Securities - Nominated Advisor                                                       Tel: +44 (0)20 7397 8900 
   and broker 
  Giles Balleny / Cameron MacRitchie (Corporate 
   Finance) 
  Michael Johnson / Julian Morse (Sales) 
 
  Walbrook PR                                         Tel: +44 (0)20 7933 8780 or intelligentultrasound@walbrookpr.com 
  Anna Dunphy / Paul McManus                                                       Mob: +44 (0)7876 741 001 / Mob: +44 
                                                                                                       (0)7980 541 893

About Intelligent Ultrasound Group

Intelligent Ultrasound (AIM: MED) develops artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market and hi-fidelity virtual reality simulators for the ultrasound training market.

Based in Cardiff and Oxford in the UK, Atlanta in the US and with representation in Beijing in Asia, the Group operates two divisions:

Clinical AI Division

Focusses on developing deep learning-based algorithms to make ultrasound machines smarter and more accessible. Products in development include ScanNav which uses machine-learning based algorithms to automatically identify and grade ultrasound images to provide scan assessment and audit of protocol-based ultrasound scanning; and AnatomyGuide, which aims to simplify ultrasound-guided needling by providing the user with real-time AI-based needle guidance software for a range of medical procedures.

Simulation Division

Focusses on hi-fidelity ultrasound education and training through simulation. Its three main products are the ScanTrainer OBGYN training simulator, the HeartWorks echocardiography training simulator and the BodyWorks Eve Point of Care and Emergency Medicine training simulator. To date over 800 simulators have been sold to almost 500 medical institutions around the world.

www.intelligentultrasound.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TSTFIFSILLITIII

(END) Dow Jones Newswires

January 08, 2020 02:00 ET (07:00 GMT)

Intelligent Ultrasound (LSE:IUG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Intelligent Ultrasound.
Intelligent Ultrasound (LSE:IUG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Intelligent Ultrasound.